phenylmethyl (2S)-4-([4-(3-(4-[(4-fluorophenyl)amino]-1-piperidinyl)-3-oxopropyl)phenyl]methyl)-2-methyl-1-piperazinecarboxylate | 923565-95-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: phenylmethyl (2S)-4-([4-(3-(4-[(4-fluorophenyl)amino]-1-piperidinyl)-3-oxopropyl)phenyl]methyl)-2-methyl-1-piperazinecarboxylate
• 英文别名: benzyl (2S)-4-[[4-[3-[4-(4-fluoroanilino)piperidin-1-yl]-3-oxopropyl]phenyl]methyl]-2-methylpiperazine-1-carboxylate
• CAS: 923565-95-1
• 化学式: C₃₄H₄₁FN₄O₃
• 分子量: 572.723
• InChiKey: FEPNARPHKARGDG-SANMLTNESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  42
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  65.1
• 氢给体数：
  1
• 氢受体数：
  6

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  ——	4-(3-(4-((4-fluorophenyl)amino)-1-piperidinyl)-3-oxopropyl)-benzaldehyde	923565-82-6	C21H23FN2O2	354.424

反应信息

• 作为反应物：
  描述：

  phenylmethyl (2S)-4-([4-(3-(4-[(4-fluorophenyl)amino]-1-piperidinyl)-3-oxopropyl)phenyl]methyl)-2-methyl-1-piperazinecarboxylate 在 palladium 10% on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 反应 2.5h， 生成 N-(4-fluorophenyl)-1-[3-(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)propanoyl]-4-piperidinamine
  参考文献：
  名称：

  WO2007/12479

  摘要：

  公开号：
• 作为产物：
  描述：

  4-(3-(4-((4-fluorophenyl)amino)-1-piperidinyl)-3-oxopropyl)-benzaldehyde 、 (S)-1-N-Cbz-2-甲基哌嗪 在 三乙酰氧基硼氢化钠 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 phenylmethyl (2S)-4-([4-(3-(4-[(4-fluorophenyl)amino]-1-piperidinyl)-3-oxopropyl)phenyl]methyl)-2-methyl-1-piperazinecarboxylate
  参考文献：
  名称：

  Discovery of N-(3-Fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the First Small Molecule Motilin Receptor Agonist Clinical Candidate

  摘要：

  N-(3-Fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine 12 (GSK962040) is a novel small molecule motilin receptor agonist. It possesses excellent activity at the recombinant human motilin receptor and also at the native rabbit motilin receptor where its agonist activity results in potentiation of the amplitude of neuronal-mediated contractions of isolated gastric antrum, tissue. Compound 12 also possesses highly promising pharmacokinetic profiles in both rat and dog, and these results, in combination with further profiling in human native tissue and an in vivo model of gastrointestinal transit in the rabbit, have led to its selection as a candidate for further development.

  DOI：

  10.1021/jm801332q

文献信息

• Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders
  申请人：Glaxo Group Limited

  公开号：EP2441763A1

  公开（公告）日：2012-04-18

  The present invention relates to novel benzylpiperazine derivatives such as compounds of formula (I), which have activity as agonists of the GPR38 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of gastrointestinal disorders.

  本发明涉及新型苄基哌嗪衍生物，如式 (I) 化合物，它们作为 GPR38 受体的激动剂具有活性 以及此类化合物或其药物组合物在治疗胃肠道疾病中的用途。
• WO2007/12479
  申请人：——

  公开号：——

  公开（公告）日：——
• Discovery of <i>N</i>-(3-Fluorophenyl)-1-[(4-([(3<i>S</i>)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the First Small Molecule Motilin Receptor Agonist Clinical Candidate
  作者：Susan M. Westaway、Samantha L. Brown、Stephen C. M. Fell、Christopher N. Johnson、David T. MacPherson、Darren J. Mitchell、James W. Myatt、Steven J. Stanway、Jon T. Seal、Geoffrey Stemp、Mervyn Thompson、Kirk Lawless、Fiona McKay、Alison I. Muir、Jonathan M. Barford、Chermaine Cluff、Sadhia R. Mahmood、Kim L. Matthews、Shiyam Mohamed、Beverley Smith、Alexander J. Stevens、Victoria J. Bolton、Emma M. Jarvie、Gareth J. Sanger

  DOI：10.1021/jm801332q

  日期：2009.2.26

  N-(3-Fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine 12 (GSK962040) is a novel small molecule motilin receptor agonist. It possesses excellent activity at the recombinant human motilin receptor and also at the native rabbit motilin receptor where its agonist activity results in potentiation of the amplitude of neuronal-mediated contractions of isolated gastric antrum, tissue. Compound 12 also possesses highly promising pharmacokinetic profiles in both rat and dog, and these results, in combination with further profiling in human native tissue and an in vivo model of gastrointestinal transit in the rabbit, have led to its selection as a candidate for further development.